Proteins involved in scaffolding, transcription regulation, and protein–protein interactions often lack suitable binding sites for conventional small-molecule inhibitors.
A new paradigm is now emerging that goes beyond inhibition and instead focuses on eliminating disease-causing proteins altogether. This approach, known as targeted protein degradation, is being driven by innovative technologies such as PROTACs (Proteolysis Targeting Chimeras). These molecules are redefining how scientists approach drug discovery by harnessing the body’s natural protein degradation machinery.
At World BI, through the Drug Discovery Innovation Programme, targeted protein degradation is recognised as one of the most transformative advances shaping the future of therapeutic innovation.
What are PROTACs?
PROTACs are bifunctional molecules designed to selectively degrade specific proteins rather than simply inhibit them.
Key Features of PROTACs Include:
- Two functional ends connected by a linker molecule
- One end binds to the target protein of interest
- The other end recruits an E3 ubiquitin ligase
- Formation of a ternary complex that tags the protein for degradation
- Utilisation of the ubiquitin–proteasome system to eliminate the target
Unlike traditional drugs, PROTACs act catalytically, meaning a single molecule can trigger the degradation of multiple target proteins.
Why Targeted Protein Degradation Matters
Targeted protein degradation offers a fundamentally different approach to drug discovery, addressing limitations of conventional therapies.
Key Advantages Include:
- Ability to target previously undruggable proteins
- Complete removal of disease-causing proteins rather than partial inhibition
- Potential for longer-lasting therapeutic effects
- Reduced likelihood of resistance compared to inhibitors
- Expanded scope of therapeutic targets across diseases
This approach opens new possibilities for treating complex diseases that have been difficult to address with traditional drug modalities.
Mechanism of Action
The mechanism of PROTACs is based on hijacking the cell’s natural protein disposal system.
The process involves:
This mechanism allows for selective and efficient removal of harmful proteins from the cell.
Applications in Drug Discovery
PROTACs are being explored across multiple therapeutic areas with promising early results.
Key Application Areas Include:
- Oncology, targeting proteins involved in cancer progression
- Neurodegenerative diseases such as Alzheimer’s and Parkinson’s
- Inflammatory and autoimmune disorders
- Rare genetic diseases with limited treatment options
- Viral infections where specific proteins drive disease progression
These applications demonstrate the versatility of targeted protein degradation in addressing diverse medical challenges.
Advantages Over Traditional Therapies
PROTACs offer several advantages compared to conventional small-molecule inhibitors.
Key Benefits Include:
- Ability to degrade non-enzymatic proteins
- Lower required drug doses due to catalytic action
- Potential to overcome drug resistance mechanisms
- Increased specificity through dual binding interactions
- Broader target space within the proteome
These advantages position PROTACs as a powerful addition to the drug discovery toolbox.
Challenges and Limitations
Despite their potential, PROTACs also present unique challenges.
Key Challenges Include:
Addressing these challenges is essential for advancing PROTACs from research to clinical use.
Role of Technology in Advancing PROTACs
Technological innovation is playing a key role in overcoming challenges associated with targeted protein degradation.
Key Enabling Technologies Include:
- Structure-based drug design for optimising PROTAC molecules
- Computational modelling of ternary complex formation
- High-throughput screening for identifying effective candidates
- Artificial intelligence for predicting degradation efficiency
- Advanced analytical techniques for studying protein interactions
These technologies are accelerating the development and optimisation of PROTAC-based therapies.
Industry and Clinical Progress
The field of targeted protein degradation is rapidly gaining traction within the pharmaceutical industry.
Recent Developments Include:
- Multiple PROTAC candidates entering clinical trials
- Increased investment from major pharmaceutical companies
- Strategic partnerships between biotech and pharma organisations
- Expansion of research into new E3 ligases and targets
- Growing interest in next-generation degradation technologies
These developments highlight the strong momentum behind this emerging field.
Future Outlook of Targeted Protein Degradation
The future of PROTACs and targeted protein degradation is highly promising.
Emerging Trends Include:
- Discovery of new E3 ligases to expand target range
- Development of oral PROTAC therapies
- Integration with precision medicine approaches
- Exploration of targeted degradation beyond proteins
- Combination therapies with existing drug modalities
As research advances, targeted protein degradation is expected to become a mainstream approach in drug discovery.
Comparison with Other Emerging Drug Modalities
To fully understand the significance of PROTACs, it is important to compare them with other emerging therapeutic approaches in drug discovery.
Key comparisons Include:
Small-molecule inhibitors:
- Block protein activity rather than removing the protein
- Often limited to proteins with well-defined binding sites
Monoclonal antibodies:
- Highly specific but generally limited to extracellular targets
- Require complex manufacturing and delivery systems
RNA-based therapies:
- Target gene expression at the RNA level
- May face challenges related to stability and delivery
Gene editing technologies:
- Modify DNA directly for long-term effects
- Associated with ethical and regulatory complexities
PROTACs:
- Remove target proteins entirely rather than inhibiting them
- Expand the range of druggable targets
- Offer a reversible and controllable mechanism compared to permanent genetic edits
PROTACs and targeted protein degradation represent a paradigm shift in drug discovery, moving beyond traditional inhibition toward selective elimination of disease-causing proteins. This innovative approach has the potential to unlock previously inaccessible therapeutic targets and transform the treatment of complex diseases.
At World BI, the Drug Discovery Innovation Programme continues to highlight groundbreaking innovations such as PROTACs that are redefining the future of pharmaceutical research. As this field evolves, targeted protein degradation is set to play a central role in delivering next-generation therapies and advancing global healthcare.